CA3167665A1 - Pegylated tetanus neurotoxins and treatment of hypotonia - Google Patents
Pegylated tetanus neurotoxins and treatment of hypotonia Download PDFInfo
- Publication number
- CA3167665A1 CA3167665A1 CA3167665A CA3167665A CA3167665A1 CA 3167665 A1 CA3167665 A1 CA 3167665A1 CA 3167665 A CA3167665 A CA 3167665A CA 3167665 A CA3167665 A CA 3167665A CA 3167665 A1 CA3167665 A1 CA 3167665A1
- Authority
- CA
- Canada
- Prior art keywords
- tent
- peg
- pegylated
- subdomain
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018902779 | 2018-07-31 | ||
| AU2018902779A AU2018902779A0 (en) | 2018-07-31 | Composition and method | |
| CA3108079A CA3108079C (en) | 2018-07-31 | 2019-07-30 | Pegylated tetanus neurotoxins and treatment of hypotonia |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3108079A Division CA3108079C (en) | 2018-07-31 | 2019-07-30 | Pegylated tetanus neurotoxins and treatment of hypotonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3167665A1 true CA3167665A1 (en) | 2020-02-06 |
Family
ID=69230503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3167665A Pending CA3167665A1 (en) | 2018-07-31 | 2019-07-30 | Pegylated tetanus neurotoxins and treatment of hypotonia |
| CA3108079A Active CA3108079C (en) | 2018-07-31 | 2019-07-30 | Pegylated tetanus neurotoxins and treatment of hypotonia |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3108079A Active CA3108079C (en) | 2018-07-31 | 2019-07-30 | Pegylated tetanus neurotoxins and treatment of hypotonia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210353724A1 (https=) |
| EP (2) | EP4134133A1 (https=) |
| JP (3) | JP2021533201A (https=) |
| KR (1) | KR20210040407A (https=) |
| CN (2) | CN120661638A (https=) |
| AU (1) | AU2019315327B2 (https=) |
| BR (1) | BR112021001520A2 (https=) |
| CA (2) | CA3167665A1 (https=) |
| MX (1) | MX2021001181A (https=) |
| NZ (1) | NZ772266A (https=) |
| SG (1) | SG11202100646SA (https=) |
| WO (1) | WO2020024002A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240268895A1 (en) | 2023-02-15 | 2024-08-15 | Canon Medical Systems Corporation | X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003200441B2 (en) * | 1998-04-29 | 2006-07-06 | Allergan, Inc. | Compositions and methods for modulating neural sprouting |
| GB9914861D0 (en) * | 1999-06-25 | 1999-08-25 | Imperial College | Tetanus toxin polypeptides |
| WO2002000172A2 (en) * | 2000-06-28 | 2002-01-03 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| US20020197278A1 (en) * | 2001-06-21 | 2002-12-26 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
| AU2003237346A1 (en) * | 2002-05-31 | 2003-12-19 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| WO2008024879A1 (en) * | 2006-08-25 | 2008-02-28 | University Of Maryland, Baltimore | Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment |
| KR101818777B1 (ko) * | 2009-04-27 | 2018-01-15 | 메르츠 파마 게엠베하 운트 코. 카가아 | 신경독 폴리펩티드의 양 및 이들의 촉매 활성 및 단백질 분해 활성의 결정수단 및 방법 |
| ES2616258T3 (es) * | 2010-03-15 | 2017-06-12 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna |
| US20170151316A1 (en) * | 2014-07-02 | 2017-06-01 | Spherium Biomed, S.L. | Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc) |
| US10704035B2 (en) * | 2015-08-27 | 2020-07-07 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
| CN106692963B (zh) * | 2016-12-28 | 2020-12-22 | 中国人民解放军军事医学科学院生物工程研究所 | 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗 |
| EP3723784A4 (en) * | 2017-12-15 | 2022-01-12 | The Medical College of Wisconsin, Inc. | USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS |
| WO2021155427A1 (en) * | 2020-02-03 | 2021-08-12 | Snoretox Pty Ltd | Composition and method |
-
2019
- 2019-07-30 AU AU2019315327A patent/AU2019315327B2/en active Active
- 2019-07-30 EP EP22183027.6A patent/EP4134133A1/en active Pending
- 2019-07-30 EP EP19843147.0A patent/EP3830110A4/en active Pending
- 2019-07-30 MX MX2021001181A patent/MX2021001181A/es unknown
- 2019-07-30 SG SG11202100646SA patent/SG11202100646SA/en unknown
- 2019-07-30 KR KR1020217006098A patent/KR20210040407A/ko not_active Ceased
- 2019-07-30 JP JP2021529491A patent/JP2021533201A/ja active Pending
- 2019-07-30 BR BR112021001520-5A patent/BR112021001520A2/pt unknown
- 2019-07-30 CA CA3167665A patent/CA3167665A1/en active Pending
- 2019-07-30 NZ NZ772266A patent/NZ772266A/en unknown
- 2019-07-30 CA CA3108079A patent/CA3108079C/en active Active
- 2019-07-30 CN CN202510841942.0A patent/CN120661638A/zh active Pending
- 2019-07-30 US US17/261,975 patent/US20210353724A1/en active Pending
- 2019-07-30 CN CN201980057158.3A patent/CN112638937B/zh active Active
- 2019-07-30 WO PCT/AU2019/050793 patent/WO2020024002A1/en not_active Ceased
-
2023
- 2023-11-20 JP JP2023196375A patent/JP7786745B2/ja active Active
-
2025
- 2025-11-25 JP JP2025203043A patent/JP2026026159A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3108079C (en) | 2023-10-10 |
| EP3830110A1 (en) | 2021-06-09 |
| AU2019315327B2 (en) | 2024-05-09 |
| NZ772266A (en) | 2022-09-30 |
| JP2021533201A (ja) | 2021-12-02 |
| CA3108079A1 (en) | 2020-02-06 |
| US20210353724A1 (en) | 2021-11-18 |
| JP2024014975A (ja) | 2024-02-01 |
| WO2020024002A1 (en) | 2020-02-06 |
| KR20210040407A (ko) | 2021-04-13 |
| SG11202100646SA (en) | 2021-02-25 |
| MX2021001181A (es) | 2021-04-19 |
| NZ789962A (en) | 2025-07-25 |
| BR112021001520A2 (pt) | 2021-04-20 |
| CN112638937B (zh) | 2025-06-17 |
| EP4134133A1 (en) | 2023-02-15 |
| JP7786745B2 (ja) | 2025-12-16 |
| EP3830110A4 (en) | 2022-03-02 |
| AU2019315327A1 (en) | 2021-02-11 |
| CN120661638A (zh) | 2025-09-19 |
| CN112638937A (zh) | 2021-04-09 |
| JP2026026159A (ja) | 2026-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3523879B2 (ja) | 輸送タンパク質用クロストリジウム属細菌毒素の修飾 | |
| ES2341140T3 (es) | Tratamiento de trastornos y afecciones neuromusculares con un seropositivo botulinico diferente. | |
| TWI776147B (zh) | 陽離子型神經毒素 | |
| KR20030033000A (ko) | 류신계 모체 및 클로스트리디움계 신경독 | |
| KR20110060903A (ko) | 지속성이 변경된 클로스트리듐 신경독 | |
| US20020197278A1 (en) | Covalent coupling of botulinum toxin with polyethylene glycol | |
| WO2009042165A2 (en) | Mutant botulinum neurotoxin serotype a polypeptide and uses thereof | |
| KR20190022548A (ko) | 트립토판 또는 타이로신으로 안정화된 액체 신경독 제형 | |
| JP2026026159A (ja) | Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療 | |
| CA3154849A1 (en) | Carrier protein with site-directed mutation and use thereof in preparation of vaccine | |
| TW202120530A (zh) | 神經障礙之治療 | |
| JP7646555B2 (ja) | 振戦治療のためのボツリヌス神経毒素の新規用途 | |
| US20230057367A1 (en) | Composition and method | |
| US20190117756A1 (en) | Immunogenic Compositions and Vaccines Derived From Bacterial Surface Receptor Proteins | |
| JP2019531698A (ja) | 活性化クロストリジウム神経毒の製造 | |
| JP2022508713A (ja) | ワクチンポリペプチド組成物および方法 | |
| RU2826569C2 (ru) | Новые способы применения ботулинического нейротоксина для лечения тремора | |
| JPH10120591A (ja) | 免疫寛容誘導剤 | |
| NZ715570B2 (en) | Cationic neurotoxins | |
| CZ20001399A3 (cs) | Prostředky a způsoby pro systémové podání orálních vakcín a terapeutických činidel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220714 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250530 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250723 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250723 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250923 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250924 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20251120 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251120 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251211 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT Effective date: 20251211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251217 |